Multidrug resistant bacteria create a challenging situation for society to treat infections. Multidrug resistance (MDR) is the reason for biofilm bacteria to cause chronic infection. Plant-based nanoparticles could be an alternative solution as potential drug candidates against these MDR bacteria, as many plants are well known for their antimicrobial activity against pathogenic microorganisms. Spondias mombin is a traditional plant which has already been used for medicinal purposes as every part of this plant has been proven to have its own medicinal values. In this research, the S. mombin extract was used to synthesise AgNPs. The synthesized AgNPs were characterized and further tested for their antibacterial, reactive oxygen species and cytotoxicity properties. The characterization results showed the synthesized AgNPs to be between 8 to 50 nm with -11.52 of zeta potential value. The existence of the silver element in the AgNPs was confirmed with the peaks obtained in the EDX spectrometry. Significant antibacterial activity was observed against selected biofilm-forming pathogenic bacteria. The cytotoxicity study with A. salina revealed the LC50 of synthesized AgNPs was at 0.81 mg/mL. Based on the ROS quantification, it was suggested that the ROS production, due to the interaction of AgNP with different bacterial cells, causes structural changes of the cell. This proves that the synthesized AgNPs could be an effective drug against multidrug resistant bacteria.

The isradipine is the potent anti hypertensive drug, which is matrix in polymeric nanoparticle by using solvent evaporation method. In this work, 3-factor, 3-level Box-Behnken design was used to optimize the process parameters like polymer concentration (A), sonication frequency (B) and sonication time (C). Three dependent variable’s particle size, entrapment efficiency and practical yield were measured as responses. Mathematical equations and response surface plots were used to relate the dependent and independent variables. The optimization model of particle size of 343.14nm, entrapment efficiency of about 83.74% and practical yield of 85.39% with A, B and C levels of 750mg, 37.5min and 40kHz respectively. The observed responses were in close agreement with the predicted values of the optimized process. The prepared nanoparticle was characterized by Fourier transform infrared spectroscopy, morphological studies and in-vitro drug release studies. The prepared nanoparticle was showed good sustained release of drug upto 24h. The anti-hypertensive study was performed on animal model. The PMMA (Poly-Methyl-Metha- Acrylate) isradipine nano particle shows fall in blood pressure was delayed and reach 152±2mmHg at 1h. The action was sustained until prolong period. Based on pharmacokinetic and pharmacodynamics parameter, the isradipine nanoparticles shows better bioavailability compare with solution form

The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells. The NP was prepared by nanoprecipitation and characterized the particle size, charge, entrapment of drug and release of it. The anti-EGFR anchored and the integrity was confirmed by SDS-PAGE. Cytotoxicity and NPs cellular uptake was analyzed with MDA-MB-468 type cancer cells and the EGFR expression was confirmed by PCR, qualitatively and quantitatively. The in-vivo antitumor activity of INP was determined by using athymic mice model and targeting efficiency was measured by calculating the PTX accumulation in the tumor plasma. The prepared INP with the size of 336.3 nm and the charge of -3.48 mV showed sustained drug release upto 48 h. The INP showed significant reduction of cancer cell viability of 10.6% for 48 h with 93 fold higher PTX accumulation in the tumor plasma compared with NPs. Based on these reports, we recommend that anti-EGFR anchored PTX loaded NP may have the ability to target the TNBC cells and improve the therapeutic action and subsidize the side effects of PTX for the treatment of TNBC.